The role of hyperglucagonemia in type 2 diabetes is still debated.
G lucagon is the main antagonist of insulin. It raises plasma glucose by reducing glycolysis and increasing gluconeogenesis and glycogenolysis (1, 2) . Glucagon secretion from a cells is triggered by hypoglycemia and inhibited by insulin from neighboring b cells. In turn, glucagon inhibits insulin secretion (2).
Unger et al. (3, 4) first postulated that elevated glucagon is a sine qua non in the development of diabetes. This marked the departure from an insulinocentric concept of type 2 diabetes pathogenesis to a bihormonal or even glucagonocentric model (4) . In a glucagonocentric model, most metabolic derangements of diabetes are caused by the disinhibition of glucagon secretion (resulting from insulin-resistant a cells or impaired insulin release), but not directly by insufficient insulin action in other tissues (4, 5) .
The issue of the different pathophysiologic models remains unresolved, at least in part due to technical difficulties: glucagon is unstable, difficult to measure because of many similar peptides in plasma (2, 6) , and its concentration is very low (7) . Furthermore, a cells are harder to isolate than their insulin-producing neighbors (8) . This impedes cellular studies.
Current data on plasma glucagon levels in (pre)diabetic human subjects are also inconsistent. Several studies have found impaired glucagon suppression during an oral glucose tolerance test (oGTT) in prediabetic and diabetic individuals when compared with healthy controls (9) (10) (11) . Other studies reported on increased fasting glucagon levels (12, 13) . In contrast, Ahrén and Larsson (14) saw no differences between impaired glucose tolerance (IGT) and normoglycemic subjects, and Wagner et al. (15) observed rising glucagon values during an oGTT in 21% to 34% of healthy, insulin-sensitive individuals. These authors even found that this pattern predicted future metabolic health.
New sandwich enzyme-linked immunosorbent assays (ELISAs) with improved specificity for glucagon became available recently, and this prompted us to re-examine the issue in a postpregnancy cohort of young women. We compared three groups of study participants with different metabolic phenotypes: a control group (normoglycemic women, who had recently completed a normoglycemic pregnancy), a normoglycemic high-risk group for type 2 diabetes [normoglycemic women after a recent pregnancy complicated by gestational diabetes (GDM)] (16, 17) , and a prediabetes/diabetes group (women with prediabetes or screening-diagnosed type 2 diabetes after GDM).
We first confirmed that average fasting plasma glucagon was higher and glucagon suppression during an oGTT was impaired in the normoglycemic high-risk and the prediabetes/diabetes groups, similar to what was seen in the majority of previous studies. However, our main research goal was to determine whether glucagon dynamics within each metabolic group were homogeneous or followed heterogeneous patterns. We used functional data analysis and unsupervised clustering to address this question.
Research Design and Methods

Study cohort
Study participants were women enrolled in the prospective, monocenter observational study Prediction, Prevention, and Subclassification of gestational and type 2 Diabetes (PPSDiab) between November 2011 and May 2016 (18) . The cohort includes women with GDM during their last pregnancy and women following a normoglycemic pregnancy in a 2:1 ratio, recruited consecutively from the diabetes center and the obstetrics department of the University Hospital (Klinikum der Universität München) in Munich, Germany.
Premenopausal women 3 to 16 months after a singleton (n = 295) or twin (n = 9) pregnancy with live birth(s) were eligible to participate. The GDM diagnosis was based on a 75-g oGTT with cut-off values for GDM according to the International Association of the Diabetes and Pregnancy Study Groups recommendations (plasma glucose: fasting 92 mg/dL, 1 hour 180 mg/dL, and 2 hours 153 mg/dL). Women without a history of GDM and either a normal 75-g oGTT (n = 294) or a normal 50-g screening oGTT (,135 mg/dL plasma glucose after 1 hour, n = 10) after the 23rd week of gestation were included in the normoglycemic group.
Exclusion criteria for this study were alcohol or substance abuse, prepregnancy diabetes, and chronic diseases requiring continuous medication, except for hypothyroidism (n = 52), bronchial asthma (n = 8), mild hypertension (n = 4), gastroesophageal reflux (n = 2), and history of pulmonary embolism resulting in rivaroxaban prophylaxis (n = 1).
Written informed consent was obtained from all study participants, and the protocol was approved by the ethical review committee of the Ludwig-Maximilians-Universität (study ID 300-11).
Data used in this analysis were collected at the baseline visit of the PPSDiab study, 3 to 16 months after the index pregnancy. In addition to the baseline visit, post-GDM women also attended yearly follow-up visits with a 75-g oGTT.
Groups
We compared three groups of women: a control group (women normoglycemic at the baseline visit and after a normoglycemic pregnancy), a normoglycemic high-risk group (women normoglycemic at the baseline visit but with GDM during the preceding pregnancy), and a prediabetes/diabetes group [women with impaired fasting glucose (IFG), IGT, combined IFG plus IGT, or screening-diagnosed type 2 diabetes at the baseline visit and with GDM during the preceding pregnancy]. IFG [fasting plasma glucose $100 mg/dL (5.6 mmol/L)], IGT [2-hour plasma glucose $140 mg/dL (7.8 mmol/L)], and diabetes [fasting plasma glucose $126 mg/dL (7.0 mmol/L) or 2-hour plasma glucose $200 mg/dL (11.0 mmol/L)] were defined according to the criteria of the American Diabetes Association (19) .
Measurements
We conducted a five-point 75-g oGTT with measurement of plasma glucose (Glucose HK Gen.3; Roche Diagnostics, Mannheim, Germany), serum insulin (chemiluminescent immunoassay; DiaSorin LIASON Systems, Saluggia, Italy), highsensitivity C-reactive protein (wide-range C-reactive protein; Siemens Health Care Diagnostics, Erlangen, Germany), and blood lipids [low-density lipoprotein and high-density lipoprotein (HDL) cholesterol and triglycerides] (enzymatic caloric test; Roche Diagnostics, Mannheim, Germany) after an overnight fast.
Plasma glucagon was measured at all five time points of oGTT with an ELISA (Glucagon ELISA; Mercodia, Uppsala, Sweden; catalog no: 10-1271-01) and also a radioimmunoassay (RIA) (Merck Millipore, Darmstadt, Germany; catalog no: GL-32K) for 283 subjects. ELISA and RIA measurements gave different results (Supplemental Table 1 ; Supplemental Fig. 1 ). In particular, suppression of plasma glucagon during the oGTT was insufficiently represented in the RIA measurement. Sensitivity and specificity of ELISA for pancreatic glucagon (amino acids 33 to 61) have been proven to be superior to RIA (20, 21) . Thus, for this analysis, we exclusively used glucagon data measured by ELISA (n = 299). Plasma for glucagon measurements was collected in BD p800 tubes (BD Biosciences, San Jose, CA), which contain specific proteinase inhibitors to stabilize glucagon and other metabolically important hormones. Plasma was immediately separated by centrifugation and directly frozen in aliquots on dry ice, before being transferred to a -80°C freezer within 1 hour from completion of the oGTT. Glucagon measurements were done in one batch and only from aliquots that had not been thawed previously.
Height and waist circumference were measured to the nearest 1 cm. Body mass and body fat mass were determined by a bioelectrical impedance analysis scale (Tanita BC-418; Tanita Corporation, Tokyo, Japan) (22, 23) . Blood pressure was calculated as the mean out of two measurements in a resting seated position.
In addition to these basic tests, all study subjects were asked to participate in a magnetic resonance imaging (MRI) measurement and an intravenous glucose tolerance test (ivGTT) on a voluntary basis.
MRI (3 Tesla System, Ingenia, or Achieva; Philips Health Care, Hamburg, Germany) included determination of abdominal visceral adipose tissue volumes and liver fat content, using an mDixon low-fat fraction map. In the ivGTT, a glucose bolus of 0.3 g/kg body weight was injected over 1 minute with subsequent frequent blood sampling at 0, 2, 4, 6, 8, 10, 20, 30, 45, and 60 minutes. The measurements were used for the calculation of first-phase insulin response.
A detailed description of the study design, anthropometric, clinical, and MRI measurements, and methodologies of blood sampling and analysis can be found elsewhere (24) .
The insulin sensitivity index (ISI) according to Matsuda and DeFronzo (25) was calculated from the oGTT:
The disposition index (DI) was calculated as (26):
ISI and insulin release 0' to 30' in the oGTT were previously validated with data from ivGTT-euglycemic clamp tests in this cohort (24) .
Glucagon suppression indices were calculated as (27) :
Late suppression ¼ ð1-½glucagon 120 ; =glucagon 30 ; Þp100%
Overall suppression ¼ ð1-½glucagon 120 ; =glucagon 0 ; Þp100%
Area under the glucagon curve was calculated using the trapezoidal rule. First-phase insulin response in the ivGTT test was calculated as the incremental area under the insulin curve from 0 to 10 minutes.
Statistical analysis
All metric and normally distributed variables are reported as mean 6 standard deviation; nonnormally distributed variables are presented as median (first quartile to third quartile). Categorical variables are presented as frequency and percentage. The KruskalWallis test was used to compare metric variables, and the x 2 or Fisher's exact test was used to compare categorical variables. For post hoc analysis, Dunn's test was used. P values ,0.05 were considered statistically significant.
Functional data analysis methods were used for the analysis of the oGTT measurements (28) . In the first step, the five-point oGTT measurements were converted into continuous, smooth curves based on B-spline basis functions (29) . Afterward, a functional principal component analysis was performed based on the fitted curves to analyze the temporal variation (28) . In the next step, a cluster analysis was conducted to identify patients with similar plasma glucagon dynamics. Hierarchical clustering was performed on the first three principal components of the functional principal component analysis via the Hierarchical Clustering on Principal Components function of Husson et al. (30) . Hierarchical clustering was performed using the Ward's criterion on the selected principal components. The number of clusters was chosen based on the growth of between-inertia. For the final partitioning, the k-means algorithm was performed with the partition obtained from the hierarchical tree as the initial partition. All statistical calculations were performed using SAS statistical software package version 9.3 (SAS Institute, Inc., Cary, NC) or R version 3.1.3 (www.r-project.org).
Results
Mean glucagon curves differ between metabolic groups
We recruited 304 women into the PPSDiab study cohort but excluded 19 from this analysis. Two women were excluded because of type 1 diabetes diagnosed during follow-up, two because of overt hyperthyroidism, and one because of an acute upper respiratory infection at baseline. Eight women were excluded from the control group due to pathological glucose tolerance at the baseline visit, and six women were excluded due to missing glucagon values.
Our final sample consisted of 285 study participants: 93 normoglycemic women after a normoglycemic pregnancy (control group), 121 normoglycemic women who had GDM (normoglycemic high-risk group), and 71 women with IFG, IGT, or newly diagnosed type 2 diabetes (prediabetes/diabetes group).
Baseline characteristics of the study cohort are shown in Table 1 . Mean age and low-density lipoprotein cholesterol were comparable, but mean blood pressure, waist circumference, triglycerides, c-reactive protein, liver fat content, intra-abdominal fat, and fasting and 2-hour plasma glucose increased and HDL cholesterol and insulin sensitivity decreased from the control over the normoglycemic high-risk to the prediabetes/diabetes groups (all significant over the three groups; results of pairwise post hoc tests shown in Table 1 ).
We next compared plasma glucagon levels during the oGTT in the three groups ( respectively). We observed no significant differences in early glucagon suppression and fasting glucagon.
Plasma glucagon patterns are heterogeneous within each metabolic group
The five-point glucagon curves in response to oral glucose were heterogeneous between individuals (Fig. 2a) . To examine this further, we calculated continuous, smooth curves from the five measurements during the oGTT based on B-spline basis functions (Fig. 2a) . Stratified by group, these curves confirmed within-group heterogeneity of plasma glucagon dynamics (Supplemental Fig. 3 ). To permit pattern identification, we added a principal component analysis of the curves. The first three principal component factors explained 79%, 17%, and 3% of curve variance, respectively (Fig. 2b) . We used these three principal components as input for an unsupervised cluster analysis (Fig. 2c) . This identified four clusters corresponding to four distinct patterns of plasma glucagon dynamics (Fig. 2d) .
Cluster 3 was the largest (n = 188; Table 2 ) and showed low mean fasting glucagon and rapid suppression during the oGTT (Figs. 2d and 3a) . Cluster 2, the second largest (n = 62), had higher mean fasting glucagon but equally rapid suppression. Cluster 1 (n = 21) had high mean fasting glucagon and delayed suppression, and cluster 4 (n = 7) had low mean fasting glucagon and a rising curve after glucose ingestion ( Fig. 3a; Table 2 ).
Cluster 1 contained the highest proportion of women from the prediabetes/diabetes group (53%), followed by cluster 2, cluster 3, and cluster 4. Women in cluster 1 had significantly higher body mass index, waist circumference, triglycerides, liver fat content, and intra-abdominal fat and lower HDL cholesterol and ISI than those in the other three clusters. The DI of cluster 1 was significantly lower than those of clusters 2 and 3 ( Table 2 ). Cluster 4 included lean, insulin-sensitive women with a tendency toward low glucose values ( Fig. 3b and 3c ; Table 2 ).
Discussion
In our first analysis, we found that women with prediabetes/screening-diagnosed type 2 diabetes had higher fasting glucagon and delayed glucagon suppression during an oGTT compared with healthy control subjects (normoglycemic women after a normoglycemic pregnancy). Normoglycemic women after GDM, a highrisk group for type 2 diabetes (16, 17) , lay in between, Table  1 and Fig. 1 ; blue = controls, gray = normoglycemic high-risk, red = prediabetes/diabetes). with values closer to and not statistically different from the control group. These results are in line with most previous studies that saw the highest fasting glucagon and most impaired glucagon suppression in subjects with diabetes, followed by those with prediabetes, and, at the low end, normoglycemic individuals (10) (11) (12) (13) 27) . In several nondiabetic cohorts, fasting glucagon was higher in insulin-resistant than in insulin-sensitive subjects (31) (32) (33) . A majority of studies also found a positive association of plasma glucagon with obesity in groups with similar glucose tolerance (11, 13, 31) . Some earlier studies had different findings. Ahrén and Larsson (14) reported that fasting and postprandial glucagon did not differ between IGT and normoglycemic subjects in 84 postmenopausal women. Wagner et al. (15) analyzed cohorts of nondiabetic individuals and found that, in 21% to 34% of subjects, glucagon was not suppressed until 120 minutes into the oGTT. These individuals were lean and insulinsensitive, and also had a favorable prognosis of insulin sensitivity over time.
In their recent study, Faerch et al. (27) described that glucagon curves differed between individuals with IFG and those with IGT. They found a smaller overall decrease in glucagon during an oGTT in the group with isolated IFG compared with isolated IGT and combined IFG + IGT. Our analysis confirms this result, with the difference in overall glucagon suppression mainly caused by the late phase of the oGTT (Supplemental Fig. 2 ; Supplemental Table 2 ).
In our second analysis, we saw that plasma glucagon dynamics in the study cohort followed four different patterns, based on an unsupervised cluster analysis. The clusters detected did not fully or even closely match the predefined metabolic groups. We consider this the main finding of this paper. Subjects from the prediabetes/ c The post hoc test for FPIR was conducted both including cluster 4 and after exclusion of cluster 4 (due to the small group size in cluster 4); in any case, the post hoc test has not reached significance.
diabetes group were overrepresented in cluster 1 (with high fasting glucagon and diminished suppression), but still only made up 50% of this cluster, which also contained 25% control subjects. Conversely, the majority of women from the prediabetes/diabetes group (n = 39; 55%) fell into cluster 3, the "most normal" cluster (with low fasting glucagon and rapid suppression). Therefore, hyperglucagonemia was not a universal prerequisite for impaired glucose metabolism or early type 2 diabetes. It only affected a subgroup of individuals. Delayed glucagon suppression was clearly associated with obesity and metabolic syndrome markers in our study. This is evident from the clinical characteristics (e.g., waist circumference, blood lipids, plasma glucose, and intra-abdominal and liver fat) of the subjects in cluster 1 compared with the other clusters ( Table 2) .
Hepatic steatosis may even be a cause of hyperglucagonemia, as it disrupts hepatic glucagon sensitivity and probably leads to reactive hypersecretion of the hormone (34) . The association of liver fat and hyperglucagonemia was found independent of the presence of disrupted glucose metabolism (34, 35) .
Impaired early insulin secretion could be another cause of delayed postprandial glucagon suppression, but we do not find evidence for this relationship. Early insulin and cpeptide levels during the oGTT and first-phase insulin Figure 3 . Means of (a) glucagon, (b) glucose, (c) insulin, and (d) c-peptide curves during oGTT stratified by the four clusters derived from the glucagon curves (Fig. 2) . secretion in the ivGTT were not reduced in the women in cluster 1. The reduced DI results from lower insulin sensitivity (ISI) in this cluster, but not from reduced early insulin secretion (insulin release 0' to 30' in the oGTT) ( Table 2 ). The a cell resistance to inhibition by insulin or a reactive glucagon hypersecretion due to a resistance of the liver is therefore the most likely explanations for our findings.
.Another noteworthy observation was the small cluster 4 (n = 7; 2.5% of participants), with low fasting glucagon, but rising glucagon levels during the oGTT. The women in this cluster were lean and insulin-sensitive and had low glucose levels. In this group, the rising glucagon probably is a physiologic response to avoid postchallenge hypoglycemia as a result of an overactive insulin response, which is not uncommon in lean, young women (36). Wagner et al. (15) associated rising glucagon during an oGTT with a favorable metabolic prognosis. Our small and probably not representative sample does not confirm this finding. Five of the 7 women in cluster 4 had had GDM (Table 2) , and all of these 5 women developed prediabetes or diabetes during the follow-up of this study (mean duration of follow-up was 38.2 months; data not shown). In our cohort, this phenotype is also much less common than reported in the previous publication. However, given the small number of subjects in cluster 4, we find these observations interesting and worth following up on, but we do not claim that they constitute scientific evidence by themselves.
Finally, we believe it is important to use highly specific glucagon assays, in particular to study postprandial glucagon dynamics. We initially used a standard RIA, which strongly underestimated glucagon suppression (Supplemental Fig. 1 ). This was probably due to cross-reactivity with other peptides cleaved from proglucagon, such as oxyntomodulin, glicentin 1-61 (N-terminally elongated glucagon), and miniglucagon. Intestinal secretion of these peptides increases in the postprandial state, masking glucagon suppression (21, (37) (38) (39) . Sandwich ELISAs, with antibodies against the N-and the C-terminal end of the glucagon molecule, circumvent this problem.
Strengths of this study are optimal preanalytic and analytic techniques plus a cohort homogeneous for age and sex and with little medication and concomitant diseases. We used functional data analysis to interpret glucagon dynamics and also consider this a strength of our work. This method can extract more of the information contained in a function than classic multivariate statistical techniques (40) (41) (42) . Together with a subsequent cluster analysis, it permits the grouping of data sets according to their curve shapes. Using a recent history of GDM to identify a high-risk cohort early in the process of type 2 diabetes development should have limited secondary metabolic abnormalities to the minimal extent possible in a human study. At the same time, the study cohort can also be interpreted as a weakness, because results may not apply to the general population. Another limitation of this analysis is its cross-sectional design, which precludes the clarification of cause-effect relationships.
We conclude that fasting hyperglucagonemia and delayed postprandial glucagon suppression associate with insulin resistance, prediabetes, and diabetes, but are, in reality, only present in subgroups of individuals. Dysglycemia can develop without elevated plasma glucagon, and elevated glucagon does not preclude normoglycemia. Fasting hyperglucagonemia and delayed suppression are strongly linked to obesity and metabolic syndrome. Rising glucagon during an oGTT may be a rare phenomenon. It occurs in insulin-sensitive individuals with a tendency toward hypoglycemia, but does not necessarily indicate metabolic health.
Our results have consequences for the pathophysiologic understanding of type 2 diabetes and for the development of precision treatments. At present, glucagon agonists and antagonists are evaluated for diabetes therapy (1, 2, 43, 44) . Based on our findings, patients should probably be stratified by glucagon values for such treatments. For those patients with hyperglucagonemia, glucagon antagonists could be an appropriate therapy, whereas for others, agonists may be useful to induce beneficial effects mediated through the glucagon receptor, such as weight loss (2, 44) .
